VIMOVOTM Shown To Decrease Nsaid-Associated Ulcers By Providing Built In Gastroprotection
AstraZeneca and POZEN announced pivotal data from two POZEN clinical trials that demonstrated that patients at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcers taking VIMOVO (naproxen/esomeprazole magnesium) experienced significantly fewer endoscopically confirmed gastric ulcers compared with patients taking enteric-coated naproxen (500 mg) alone.
|
|
Superior Phase III trial results with Tasigna bring new hope to patients with early-stage chronic myeloid leukemia
In a large Phase III clinical trial, Tasigna demonstrated greater efficacy over Gleevec in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology , in New Orleans, Louisiana.
Tasigna results showed statistically significant improvement over Gleevec* in every measure of efficacy, including major molecular response (MMR), complete cytogenetic response (CCyR), and prevention of progression to the accelerated or blast crisis phases.
Submitted by:
Cohn & Wolfe
2 Bloor Street East
Toronto, Ontario M4W 1A8
416.924.5700
www.cohnwolfe.ca
|
Pharmacy For Sale
in Ontario
Well established pharmacy in Southwestern Ontario.
Total prescriptions are over 28,000 with sales exceeding 1.9 M.
Serious Buyers Only Please.
Contact John at
(519) 595-8300
|
